PubMed CNKI CBM VIP WanFang Data THP

Size: px

Start display at page:

Download "PubMed CNKI CBM VIP WanFang Data THP"

Loraine Hines
5 years ago
Views:

1 Review Articles Chin J Evid-based Med 2013, 13(2): THP ADM PubMed CNKI CBM VIP WanFang Data THP ADM NHL RCT RevMan 5.0 Meta 15 RCT Meta THP CTOP C T O P ADM CHOP C H O POR= %CI P=0.006 THP CTOP ADM CHOP OR= %CI P< OR= %CI P= OR= %CI P=0.05 OR= %CI P=0.25 OR= %CI P=0.17 OR= %CI P=0.95 ADM CHOP THP CTOP Meta Effectiveness and Safety of Chemotherapy Regimens Represented by Pirarubicin versus Adriamycin Hydrochloride for Non-Hodgkin Lymphoma in Mainland China: A Meta-Analysis LI Hui, WANG Xiao-dong, WANG Chun-sen Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People s Hospital, Chengdu , China Abstract Objective To evaluate the effectiveness and safety of chemotherapy regimens represented by pirarubicin (THP) vs. adriamycin hydrochloride (ADM) for non-hodgkin lymphoma (NHL) in mainland China. Methods The randomized controlled trials (RCTs) about THP vs. ADM for treating NHL were collected in the databases such as CNKI, CBM, VIP and WanFang Data, and the references of the included studies were also retrieved manually, with the retrieval time from January 1989 to September According to the inclusion and exclusion criteria, two reviewers independently screened articles, extracted data, and assessed the methodological quality of the included studies. Then metaanalysis was performed using RevMan 5.0 software. Results A total of 15 RCTs involving patients were included. The results of meta-analysis showed that: a) As for the total effective rate, the CTOP (C: cyclophosphamide, T: pirarubicin, O: vincristine, P: prednison) regimen was superior to the CHOP (C: cyclophosphamide H: adriamycin hydrochloride, O: vincristine, P: prednison) regimen with a significant difference (OR=1.07, 95%CI 1.02 to 1.12, P=0.006); and b) As for the safety, there were significant differences between the two groups in the incidence of cardiac toxicity (OR=0.42, 95%CI 0.30 to 0.57, P< ), gastrointestinal tract response (OR=0.69, 95%CI 0.56 to 0.85, P= ) and liver damage (OR=0.69, 95%CI 0.48 to 1.00, P=0.05). But no significant differences were found between the two groups in the incidence of mye1osuppression: the decreased hemoglobin (OR=0.83, 95%CI 0.61 to 1.14, P=0.25), leucopenia (OR=0.85, 95%CI 0.68 to 1.07, P=0.17), and thrombocytopenia (OR=0.99, 95%CI 0.70 to 1.39, P=0.95). Conclusion Based on the domestic evidences at current and compared with CHOP regimen represented by ADM, CTOP regimen represented by THP for treating NHL DOI: / lihui606606@163.com Editorial Board of Chin J Evid-based Med

2 2013, 13(2): shows a higher total effective rate and less side effects. However, more high quality, large sample and double blind RCTs are required to prove this conclusion for the quality and quantity limitation of the included studies. Key words Pirarubicin; Adriamycin hydrochloride; Non-Hodgkin lymphoma; Randomized controlled trial; Metaanalysis; Systematic review non-hodgkin lymphoma NHL NHL [1] ADM CHOP ADM ADM CHOP CHOP THP ADM THP ADM [2,3] NHL [4,5] RCT NHL THP CTOP ADM CHOP WHO [6] CR PR SD PD CR+PR RR WHO [7] PubMed CNKI CBM VIP WanFang Data THP ADM NHL WanFang Data Cochrane [8] RCT Cochrane RevMan 5.0 Meta 1 #1 #2 #3 #4 #5 #6 ADM #7 THP #8 #1 OR #2 OR #3 OR #4 #9 #6 AND #7 #10 #5 AND #8 AND #9 177

3 Review Articles OR 95%CI Z Z P P 0.05 P<0.10 α=0.10 [9] I 2 I 2 <25% 25% I 2 50% I 2 >50% P 0.10 I 2 50% Meta P<0.10 I 2 >50% Meta RCT [2-5,10-20] NHL Chin J Evid-based Med 2013, 13(2): CR+PR n=233 n=284 n=80 n=28 n=15 Meta n=15 1 n=297 n=52 n=13 1 / / / / T C T C T C T C 2010 [2] 21/10 19/ /13/9/4 5/12/10/3 CTOP CHOP [3] 54/40 54/ /52/18/12 CTOP CHOP [4] 38/20 38/ /10/25/19 CTOP CHOP [5] 32/19 26/ /10/32/9 0/8/28/7 CTOP CHOP [10] 14/9 12/ /7/8/4 3/8/7/4 CTOP CHOP [11] 21/9 23/ /9/6/3 8/7/7/8 CTOP CHOP [12] 8/5 9/ /8 * 5/9 * CTOP CHOP [13] 25/17 26/ /6/25/11 0/4/ CTOP CHOP [14] /5/10/6 3/6/13/4 CTOP CHOP [15] 37/28 42/ /31/16/4 10/26/19/8 CTOP CHOP [16] 69/47 69/ /35/13 # CTOP CHOP [17] 40/24 40/ /18/26/10 CTOP CHOP [18] /31/16/4 10/26/19/8 CTOP CHOP [19] 70/59 37/30 18/36/29/46 10/18/16/23 CTOP CHOP 6 8 Zhai 2010 [20] 126/79 173/81 117/88 * 156/97 * CTOP CHOP 3 10 T C * / # / / Editorial Board of Chin J Evid-based Med

4 2013, 13(2): P=0.85 I 2 =0% Meta OR= %CI P= ADM CHOP CHOP CHOP THP [2] 2012 [3] 2011 [4] 2006 [5] 2010 [10] 1999 [11] 2003 [12] 2001 [13] 2011 [14] 2009 [15] 2009 [16] 2008 [17] 2008 [18] 2010 [19] Zhai 2010 [20] 2 CTOP CHOP NHL Meta

5 Review Articles Chin J Evid-based Med 2013, 13(2): T/C T/C Hb WBC PLt T/C T/C 2010 [2] 2/3 2/4 2/2 1/3 2/ [3] 26/29 38/32 7/5 3/8 4/ [4] 16/19 3/3 6/6 2/3 2/ [5] 29/26 38/32 7/5 3/8 4/ [10] 14/13 15/16 2/2 1/4 2/ [11] 16/31 6/9 12/16 7/9 2/8 1/ [12] 5/7 6/6 0/2 0/2 0/ [13] 27/38 12/12 42/40 17/16 3/7 3/ [14] 13/15 1/1 5/5 6/8 2/8 3/ [15] 35/38 3/2 31/39 2/3 1/9 3/ [16] 35/37 6/6 6/6 6/6 5/9 3/ [17] 2/2 5/6 2/2 1/ [18] 35/38 3/2 31/39 2/3 1/9 3/ [19] 49/26 81/37 5/6 6/4 5/3 Zhai 2010 [20] 106/160 75/ /191 25/27 31/51 22/41 T C 4 NHL Meta OR 95%CI P < HB WBC PLt [21] ADM ADM 4 DNA DNA [22,23] [24] THP ADM 1/7 ADM 1/4 THP mg/m 2 ADM NHL THP 2 1 [25] THP CTOP ADM CHOP NHL THP ADM THP 180 PubMed CTOP CHOP Meta NHL Meta 2 [19,20] NHL THP CTOP ADM CHOP 1,. B., 2007, 4(6): AVP AVP., 2010, 7(4): ,,,.., 2012, 18(2): ,, Editorial Board of Chin J Evid-based Med

6 2013, 13(2): , 2011, 28(7): ,,. ( 51 )., 2006, 16(6): :, 1998: ,,,.. :, 1996: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version [updated March 2011]. The Cochrane Collaboration, Available from org. 9.. :, 2003: , 4(2): ,,,.., 1999, 6(6): ,.., 2003, 15(1): , (2): ,,.., 2011, 32(35): ,,.., 2009, 2(5): ,,.., 2009, 16(5): ,,. CTOP CHOP., 2008, 21(7): ,,,.., 2008, 17(5): ,,,. CTOP CHOP., 2010, 31(10): Zhai LZ, Guo CC, Cao YB, et al. Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-hodgkin s lymphoma: single center, 15-year experience. Int J Hematol, 2010, 91(1): ,, , 22(22): ,,,. /., 2009, 22(4): ,,,. 37., 2005, 17(1): T., 1999, 48(3): Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP- COP regimens in the treatment of newly diagnosed aggressive non- Hodgkin s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer ResClin Oncol, 2004, 130(2):

2122: Testicular/Germ Cell Cancer Post-HSCT Data

2122: Testicular/Germ Cell Cancer Post-HSCT Data Registry Use Only Sequence Number: Date Received: Key Fields Sequence Number ELSE GOTO Date Received: Date Received: - - ELSE GOTO CIBMTR Center Number